372 related articles for article (PubMed ID: 32725342)
1. Molecular epidemiology and diagnostics of KRAS mutations in human cancer.
Timar J; Kashofer K
Cancer Metastasis Rev; 2020 Dec; 39(4):1029-1038. PubMed ID: 32725342
[TBL] [Abstract][Full Text] [Related]
2. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Haley L; Tseng LH; Zheng G; Dudley J; Anderson DA; Azad NS; Gocke CD; Eshleman JR; Lin MT
Mod Pathol; 2015 Oct; 28(10):1390-9. PubMed ID: 26226847
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R
PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508
[TBL] [Abstract][Full Text] [Related]
4. The Abundance of KRAS and RAS Gene Mutations in Cancer.
Stites EC
Methods Mol Biol; 2024; 2797():13-22. PubMed ID: 38570449
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer.
Morris VK; Lucas FAS; Overman MJ; Eng C; Morelli MP; Jiang ZQ; Luthra R; Meric-Bernstam F; Maru D; Scheet P; Kopetz S; Vilar E
Ann Oncol; 2014 Oct; 25(10):2008-2014. PubMed ID: 25009008
[TBL] [Abstract][Full Text] [Related]
6. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
Waters AM; Der CJ
Cold Spring Harb Perspect Med; 2018 Sep; 8(9):. PubMed ID: 29229669
[No Abstract] [Full Text] [Related]
7. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
[TBL] [Abstract][Full Text] [Related]
8. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific.
Cook JH; Melloni GEM; Gulhan DC; Park PJ; Haigis KM
Nat Commun; 2021 Mar; 12(1):1808. PubMed ID: 33753749
[TBL] [Abstract][Full Text] [Related]
9. KRAS Alleles: The Devil Is in the Detail.
Haigis KM
Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387
[TBL] [Abstract][Full Text] [Related]
10. Selective targeting of the oncogenic
Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
[No Abstract] [Full Text] [Related]
11. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
Laurent-Puig P; Pekin D; Normand C; Kotsopoulos SK; Nizard P; Perez-Toralla K; Rowell R; Olson J; Srinivasan P; Le Corre D; Hor T; El Harrak Z; Li X; Link DR; Bouché O; Emile JF; Landi B; Boige V; Hutchison JB; Taly V
Clin Cancer Res; 2015 Mar; 21(5):1087-97. PubMed ID: 25248381
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
[TBL] [Abstract][Full Text] [Related]
13. Association between clinicopathological characteristics and RAS mutation in colorectal cancer.
Rimbert J; Tachon G; Junca A; Villalva C; Karayan-Tapon L; Tougeron D
Mod Pathol; 2018 Mar; 31(3):517-526. PubMed ID: 29052598
[TBL] [Abstract][Full Text] [Related]
14. Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining.
Tayou J
Cell Oncol (Dordr); 2018 Aug; 41(4):395-408. PubMed ID: 29679238
[TBL] [Abstract][Full Text] [Related]
15. Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report.
El Agy F; El Bardai S; El Otmani I; Benbrahim Z; Karim MH; Mazaz K; Benjelloun EB; Ousadden A; El Abkari M; Ibrahimi SA; Chbani L
PLoS One; 2021; 16(3):e0248522. PubMed ID: 33784337
[TBL] [Abstract][Full Text] [Related]
16. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
17. Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Szumiłło J; Trojanowski T; Milanowski J
Clin Exp Med; 2016 May; 16(2):169-76. PubMed ID: 25902737
[TBL] [Abstract][Full Text] [Related]
18. Extended-spectrum of
Basdemirci M; Zamani A; Zamani AG; Findik S; Yildirim MS
Indian J Cancer; 2022; 59(2):236-243. PubMed ID: 34380837
[TBL] [Abstract][Full Text] [Related]
19. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
20. The expressed mutational landscape of microsatellite stable colorectal cancers.
Sveen A; Johannessen B; Eilertsen IA; Røsok BI; Gulla M; Eide PW; Bruun J; Kryeziu K; Meza-Zepeda LA; Myklebost O; Bjørnbeth BA; Skotheim RI; Nesbakken A; Lothe RA
Genome Med; 2021 Sep; 13(1):142. PubMed ID: 34470667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
